Apollo Neuroscience Inc.

Apollo Neuroscience operates at the intersection of consumer wellness wearables, digital health, sleep technology, and neuroscience. Unlike tracking-oriented products that primarily measure sleep, heart rate, or activity, Apollo’s core proposition is an active intervention: gentle vibrations intended to influence stress resilience, focus, recovery, sleep, and heart-rate variability. Apollo differentiates through its touch-therapy framing, non-invasive and drug-free approach, SmartVibes AI personalization, and a product portfolio spanning the Apollo Wearable, Apollo Clip, companion apps, and Apollo Sessions. The company also claims more than 30 clinical studies and reported a 46-minute average sleep improvement in a study announced in July 2026, giving it a stronger evidence-led narrative than many general-purpose wellness devices. Its positioning remains wellness rather than treatment of psychiatric disorders, which limits medical claims but broadens consumer accessibility. Distribution across direct consumer, clinician, wholesale, SDK licensing, and employer channels provides multiple routes to market, although public information is insufficient to assess market share or comparative revenue scale.

Apollo’s growth trajectory shows a shift from funded hardware development toward a broader platform spanning devices, software, clinical evidence, and employer distribution. The company raised $21.2 million across five recorded rounds, including $6 million in a 2021 Series A and $15 million in a 2022 Series A led by Noetic Fund. Product development has expanded beyond the original wearable: SmartVibes AI, introduced in 2023, uses sleep data from Apollo devices and Oura Ring to adjust vibration patterns, while Apollo Sessions launched on Jan 30, 2025 to make the technology available through an iPhone app. Apollo for Business, introduced in 2024, opened an employer-focused route centered on sleep and stress. Clinical communications became a more prominent growth lever in 2025 and 2026, including a study on burnout among medical and pharmacy students and the July 2026 sleep study reporting 46 additional minutes per night. The employee record lists five current positions and a 11–50 employee range, suggesting a focused operating footprint. Public hiring detail and revenue metrics remain limited, so scale and commercial conversion cannot be independently assessed.